4.8 Article

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression

Journal

NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-07305-8

Keywords

-

Funding

  1. Associazione Italiana per la Ricerca sul Cancro (AIRC), AIRC 5 x 1000 Molecular Clinical Oncology Special Program, Milan, IT [9965]
  2. National Cancer Institute [CA190045, CA186781, CA168762, CA195688]
  3. AIRC/FIRC
  4. NATIONAL CANCER INSTITUTE [R01CA190045, R01CA234181, U54CA224018, P50CA186781, R01CA195688, R01CA168762] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The gut microbiota has been causally linked to cancer, yet how intestinal microbes influence progression of extramucosal tumors is poorly understood. Here we provide evidence implying that Prevotella heparinolytica promotes the differentiation of Th17 cells colonizing the gut and migrating to the bone marrow (BM) of transgenic Vk*MYC mice, where they favor progression of multiple myeloma (MM). Lack of IL-17 in Vk*MYC mice, or disturbance of their microbiome delayed MM appearance. Similarly, in smoldering MM patients, higher levels of BM IL-17 predicted faster disease progression. IL-17 induced STAT3 phosphorylation in murine plasma cells, and activated eosinophils. Treatment of Vk*MYC mice with antibodies blocking IL-17, IL-17RA, and IL-5 reduced BM accumulation of Th17 cells and eosinophils and delayed disease progression. Thus, in Vk*MYC mice, commensal bacteria appear to unleash a paracrine signaling network between adaptive and innate immunity that accelerates progression to MM, and can be targeted by already available therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available